Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks. In this ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...